Catherine Arnold

This is half the savings that Pfizer achieved with its recently announced program.

This is half the savings that Pfizer achieved with its recently announced program.

We just can't get there. Maybe they see something we don't see.

We just can't get there. Maybe they see something we don't see.

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to read more

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.

The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological read more

The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really read more

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.